Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points - Wikidata - awgldk - TriplyDB

Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points

Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points

http://www.wikidata.org/entity/Q35004750

about

Expert perspectives on biosimilar monoclonal antibodies in breast cancer Clinical considerations for the development of biosimilars in oncology Time-dependent endpoints as predictors of overall survival in multiple myeloma Relationship between progression-free survival and overall survival in chronic lymphocytic leukemia: a literature-based analysis.Proof of concept to clinical confirmation: evolving clinical trial designs for targeted agents.Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology.Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies.Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers.Biosimilar monoclonal antibodies in lymphoma: a critical appraisal.Model-based meta-analysis of progression-free survival in non-Hodgkin lymphoma patients Acceptance of surrogate end points in clinical trials supporting approval of drugs for cancer treatment by the Japanese regulatory agency.Relationship between response rates and median progression-free survival in non-Hodgkin's lymphoma: A meta-analysis of published clinical trials.Unmet needs in the first-line treatment of follicular lymphoma.Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders' Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL).

P2860

Q26865410-1BD56C21-DC34-4EC3-846F-82B85C0A7A7C Q28081768-640AA4F9-1C5F-4B9D-8059-4E528C8AFB79 Q30538040-C296E987-19CB-4F8D-BF6B-199C5977DA43 Q35714606-16A6F65B-BD42-473C-ACF3-7671B193C912 Q36021866-67C44F09-1B1E-451B-8D62-C412797FE2B0 Q36349459-B573AD04-BFB9-4591-B2ED-DE19F32CA07C Q37962701-4D7A5FD4-F292-42D8-A557-71E57B2AE647 Q38259501-D24CE583-C0A2-4832-B26B-678D5C127F50 Q38394272-16289C5B-32DA-4DC3-8E45-9465B1291921 Q41622226-E65E80AC-4F8B-47A8-8CA2-6EB02926CF29 Q47591645-5FE4EFFB-ECFA-4128-BB0E-F2B9D5308C98 Q50529551-7A0B2A3F-3C7A-4B53-A471-98B5028E8594 Q50710717-F8C2E975-56BB-49B9-BBD0-5A105D9D7E97 Q52603250-E98FE204-377B-433F-A763-8C46F4B74354

P2860

Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points

http://www.wikidata.org/entity/Q35004750

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Identification of potential su ...... nd overall survival end points

@ast

Identification of potential su ...... nd overall survival end points

@en

type

label

Identification of potential su ...... nd overall survival end points

@ast

Identification of potential su ...... nd overall survival end points

@en

prefLabel

Identification of potential su ...... nd overall survival end points

@ast

Identification of potential su ...... nd overall survival end points

@en

P1433

Q35004750-B25C80A8-A59E-4C0F-A548-00169FA45726

P1476

Q35004750-8E72A6F3-930A-45C1-946D-38A322BD9B1B

P2093

Q35004750-74D79E23-4900-4F51-BD5B-26F00029506B

Q35004750-82EACCDA-C1A6-4240-8911-380DBF8F6B71

Q35004750-B346CADF-CB28-4FB1-8BAC-95A03929ADF4

P2860

Q35004750-0368845F-C3D2-443E-B31C-4388AFA1E9A9

Q35004750-057541AE-7BEF-4E94-A988-ADC89A923976

Q35004750-11C358CA-EE8D-4DEE-8DF3-70F85F786461

Q35004750-172F5DFC-0F14-4B68-BBF7-0902E5655570

Q35004750-2065F5A2-1C7B-41C3-9430-3982F83917B7

Q35004750-23FA8B41-30F0-40F0-910C-A26F1A296601

Q35004750-248DCDBA-5566-47F4-912F-CB65EF3AA803

Q35004750-259EF442-24A5-4D69-9595-8A4B8FF84E86

Q35004750-28036ACC-60B5-4249-8C72-0455043E5AD6

Q35004750-34C083F6-A8A8-42C1-9298-6D2D85C35B2F

P304

Q35004750-08439518-AB39-4F15-A921-446B638F93DF

P31

Q35004750-E6594B69-F775-424B-9EFA-0C301F7CB1A6

P356

Q35004750-9D62A8D0-73E8-4189-A556-721E6FA92398

P433

Q35004750-0A445E14-A861-49FA-BE97-385B536053BC

P478

Q35004750-41AD6798-ABD0-4A12-A4B1-1A4CB568181A

P577

Q35004750-034C842B-AD10-4E05-B054-C1071035AE31

P5875

Q35004750-613E4A9C-07B4-4C4D-885C-379EB3B92E2C

P698

Q35004750-F0C22348-28D9-4462-9B48-195D2FD90BDD

P932

Q35004750-91054452-566A-428D-BBB0-4590EAA4590B

P356

P1433

Annals of Oncology

P1476

Identification of potential su ...... nd overall survival end points

@en

P2093

L Lee

http://www.w3.org/2001/XMLSchema#string

L Wang

http://www.w3.org/2001/XMLSchema#string

M Crump

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.

Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle c

Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

EORTC study of non-Hodgkin's lymphoma: phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphoma.

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.

Detecting an overall survival benefit that is derived from progression-free survival

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

P304

1392-1403

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDQ615

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49784983

http://www.w3.org/2001/XMLSchema#string

P698

21266519

http://www.w3.org/2001/XMLSchema#string

P932

3101365

http://www.w3.org/2001/XMLSchema#string